Evidence map›Paper›PMID 37615884›Full record

ArticleNeurochemical research2024

Neuroprotective Effects of Ferrostatin and Necrostatin Against Entorhinal Amyloidopathy-Induced Electrophysiological Alterations Mediated by voltage-gated Ca

Soudabeh Naderi, Fereshteh Motamedi, Hamid Gholami Pourbadie, Shahrbanoo Rafiei, Fariba Khodagholi, Nima Naderi, Mahyar Janahmadi

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Soudabeh NaderiSchool of Medicine, Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Fereshteh MotamediNeuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hamid Gholami PourbadieDepartment of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran.
Shahrbanoo RafieiNeurobiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Fariba KhodagholiNeuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Nima NaderiDepartment of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahyar JanahmadiNeuroscience Research Center, Department of Physiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Janahmadi@sbmu.ac.ir.
Shahid Beheshti University of Medical Sciences · IRPasteur Institute of Iran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease that is the main form of dementia. Abnormal deposition of amyloid-beta (Aβ) peptides in neurons and synapses cause neuronal loss and cognitive deficits. We have previously reported that ferroptosis and necroptosis were implicated in Aβ

Indexed as

Alzheimer DiseaseNeurodegenerative DiseasesNeuroprotective AgentsAmyloid beta-PeptidesCalcium ChannelsDentate GyrusHumansPeptide FragmentsAmyloid beta-PeptidesCalcium ChannelsNeuroprotective AgentsPeptide FragmentsCa2+ currentsEntorhinal amyloidopathyFerroptosisNecroptosisWhole-cell patch-clamp

Identifiers

PMID37615884
OpenAlexW4386116718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.